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Abstract
Background: Several studies have noted that genetic variants of SCARB1, a lipoprotein receptor involved in reverse
cholesterol transport, are associated with serum lipid levels in a sex-dependent fashion. However, the mechanism
underlying this gene by sex interaction has not been explored.
Methods: We utilized both epidemiological and molecular methods to study how estrogen and gene variants
interact to influence SCARB1 expression and lipid levels. Interaction between 35 SCARB1 haplotype-tagged
polymorphisms and endogenous estradiol levels was assessed in 498 postmenopausal Caucasian women from the
population-based Rancho Bernardo Study. We further examined associated variants with overall and SCARB1 splice
variant (SR-BI and SR-BII) expression in 91 human liver tissues using quantitative real-time PCR.
Results: Several variants on a haplotype block spanning intron 11 to intron 12 of SCARB1 showed significant gene
by estradiol interaction affecting serum lipid levels, the strongest for rs838895 with HDL-cholesterol (p = 9.2 × 10
-4)
and triglycerides (p = 1.3 × 10
-3) and the triglyceride:HDL cholesterol ratio (p = 2.7 × 10
-4). These same variants
were associated with expression of the SR-BI isoform in a sex-specific fashion, with the strongest association found
among liver tissue from 52 young women <45 years old (p = 0.002).
Conclusions: Estrogen and SCARB1 genotype may act synergistically to regulate expression of SCARB1 isoforms and
impact serum levels of HDL cholesterol and triglycerides. This work highlights the importance of considering sex-
dependent effects of gene variants on serum lipid levels.
Background
The scavenger receptor class B type 1 (SR-BI) is a
plasma membrane protein that binds high density lipo-
protein (HDL) with high affinity and mediates selective
uptake of cholesterol esters by the liver[1,2]. Besides its
role as a functional HDL receptor involved in reverse
cholesterol transport, SR-BI also participates in the
metabolism of Apolipoprotein B-containing lipoproteins,
including low density lipoprotein (LDL)[3,4] and very
low density lipoprotein (VLDL)[5,6]. In addition, studies
have implicated SR-BI as a key co-receptor mediating
infection with the hepatitis C virus[7], where chronic
infection is characterized by marked lipid changes
reflecting viral dependence on host lipid metabolism for
replication and assembly[8]. The full length gene encod-
ing SR-BI (gene symbol SCARB1) is comprised of 13
exons that are alternatively spliced to produce two
major transcripts: the full length SR-BI and the splice
variant SR-BII, in which exon 12 is skipped. SR-BI and
SR-BII splice forms are conserved in both the mouse
and rat genomes, have different tissue distributions and
may influence cellular cholesterol trafficking and home-
ostasis in different ways[9]. SR-BII is reported to be a
minor splice variant in human liver and has been shown
to be less efficient at reverse cholesterol transport[10].
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ciation studies, targeted investigations into the associa-
tion between SCARB1 single nucleotide polymorphisms
(SNPs) and serum lipids have been limited to a handful
of polymorphisms in either exon 1, intron 5 or exon 8.
These studies have found polymorphisms of SCARB1
associated with serum levels of triglycerides [11-14],
HDL cholesterol [11-18], LDL cholesterol[11,12,17] and
VLDL[12]. Interestingly, many of these studies show dif-
ferent effects of the polymorphisms in men and women,
suggesting a possible mediating role of sex hormones
[11-15,17,18].
Estrogen is known to have a profound impact on
serum lipid levels, resulting in a decrease in LDL choles-
terol and triglycerides, affording younger women relative
protection from coronary artery disease[19]. Estrogen is
also a potent regulator of SCARB1, influencing the rela-
tive expression of SR-BI and SR-BII isoforms[20]. In
rodent models, treatment with high doses of estrogen
suppressed liver expression of full length SR-BI isoform,
but increased expression of the splice variant SR-BII
[21,26]. Similarly, treatment of human HepG2 liver cell
lines with estradiol has been shown to result in a down-
regulation of SR-BI and up-regulation of the SR-BII
splice form[24,27].
We previously described how the association between
SCARB1 gene variants and HDL cholesterol levels varied
by estrogen therapy status among postmenopausal
women from the community-based Rancho Bernardo
Study [28]. In the current study, we took a comprehen-
sive SNP tagging approach to identify SCARB1 genetic
variation influencing lipid levels in an estrogen depen-
dent manner. We examined interaction between
SCARB1 genotypes and endogenous estradiol levels
among postmenopausal women, where levels of estradiol
are lower than premenopausal women but not subject to
monthly fluctuations. We further explored the func-
tional consequences of SCARB1 genetic variation on
alternative splicing of SCARB1 in a large series of
human liver tissues. We report here how both endogen-
ous estrogen and SCARB1 genotype synergistically influ-
ence serum levels of HDL cholesterol and triglycerides
in human populations and how this effect may be
mediated through expression of the SR-BI isoform.
Methods
Rancho Bernardo Study
The Rancho Bernardo Study is a population-based
cohort of white men and women, established during
1972-1974 in the suburban community of Rancho Ber-
nardo, California[29]. The present study utilizes medical
history, current medication use and health behaviors
assessed from standardized questionnaires, anthropo-
metric measures, and laboratory measures collected on
women between 1984 and 1987 during a follow-up visit
focusing on diabetes and cardiovascular disease (visit 4).
At the time of this visit, the average age of subjects was
70 years and the vast majority of women were postmeno-
pausal. Therefore, we restricted our analyses to postme-
nopausal women. Subjects who participated in this visit
provided morning blood samples obtained after an over-
night fast and used to measure lipid and lipoprotein
levels. Fasting serum cholesterol, triglyceride and HDL
cholesterol levels were measured in a Center for Disease
Control-Certified Lipid Research Clinic laboratory. Total
cholesterol and triglyceride levels were measured by
enzymatic techniques using an ABA-200 biochromatic
analyzer (Abbott Laboratories, Irving, TX). HDL choles-
terol was measured after precipitation of the other lipo-
proteins with heparin and manganese chloride. LDL
cholesterol was estimated using the Friedewald formula
[30]. Current use of estrogen therapy was validated by
examination of pills or prescriptions brought to the clinic
for that purpose and was classified as current versus
non-current use. Endogenous estradiol in non-hormone
using women was measured between 1992 and 1993 by
radioimmunoassay after solvent extraction and column-
chromatography[31] using first-thawed fasting morning
specimens from the 1984-1987 venipuncture. Measure-
ments were performed in the endocrinology research
laboratory of S. S. C. Yen (Department of Reproductive
Medicine, University of California-San Diego, La Jolla,
CA). Serum estradiol is stable for >10 years when kept
frozen at -70C (personal communication from S. Yen).
The sensitivity and the intra- and inter-assay coefficients
of variation, respectively, were 11 pmol/L, 5.9% and
7.1%. Because of a skewed distribution, estradiol mea-
sures were grouped into tertiles with the following cut-
offs: low (7-17 pmol/L); medium (18-24 pmol/L); high
(25-58 pmol/L). The 52 women with estradiol levels
below the lower limit of detection (representing about
10% of the cohort) were included in the low estradiol
group. Five women with estradiol levels above normal
for postmenopausal women (>217 pmol/L) were
excluded.
There were a total of 899 post-menopausal women
who participated in visit 4 and provided a blood sample
for DNA. There were 83 SCARB1 SNPs with minor
allele frequency >0.05 in Caucasians in the HapMap
database. The Tagger program in Haploview software
version 3.2 [32] was used to select 35 haplotype tagged
SNPs in the SCARB1 gene having minor allele frequen-
cies of >0.05 and capturing all alleles with correlations
(r
2) >0.80 among Caucasians (Table 1). Of the 899
women with blood samples available, 793 were success-
fully genotyped for SCARB1 SNPs. We further excluded
six women missing primary lipid data; an additional
nine women on lipid lowering therapy; and 280 women
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measures were not measured, leaving a final sample of
498 women.
Liver Samples
Post-mortum liver tissues from 93 otherwise healthy
Caucasian adults were purchased from the National
Institute of Child Health and Human Development
Brain and Tissue Bank for Developmental Disorders
(University of Maryland, Baltimore, MD). All had a post
mortem interval (PMI) <24 hours. A demographic
description is included in Table 2. The human hepa-
toma (HepG2) cell line was obtained from American
Type Culture Collection (Manassas, VA).
RNA extraction and cDNA synthesis from liver tissue
Total RNA was extracted from liver sample (100 mg)
using TRIzol reagent (Invitrogen, Carlsbad, CA) fol-
lowed by purification with RNeasy kit using an on-col-
umn DNase treatment (Qiagen, Inc., Valencia, CA)
following the manufacturer’s protocol. RNA concentra-
tion was determined spectrophotometrically at 260 nm,
while the quality of the purification was determined by
260 nm/280 nm ratio. Additionally, quality of sample
and lack of significant degradation products was con-
firmed on an Agilent Bioanalyzer. Next, cDNA was
synthesized using MultiScribe RT enzyme (Applied Bio-
systems, Foster City, CA) under the following condi-
tions: 10 min at 25°C and 120 min at 37°C.
Real time PCR
Real-time PCR was used to quantify human SCARB1
mRNA levels (SR-BI isoform, SR-BII isoform and overall
SCARB1) using commercially available TaqMan assays.
Briefly, each liver sample was assayed by quantitative
real-time PCR using the ABI 7900 to determine the
level of the target message relative to mRNA encoding
the human peptidylprolyl isomerase A (PPIA).T h i s
housekeeping gene has been shown to be among the
most stable in studies of mouse liver, making it ideal for
normalization in liver gene expression studies[33]. Each
cDNA (50 ng) was amplified in duplicate using TaqMan
Gene Expression PCR master mix reagent (Applied Bio-
systems, Foster City, CA) under the following condi-
tions: 2 min at 50°C, 10 min at 95°C, 40 cycles: 15 sec
at 95°C, and 1 min at 60°C. The different target cDNAs
were amplified using the following ABI MGB probe and
primer set assays (Applied Biosystems, Foster City, CA):
ID HS00969822_m1 for overall SCARB1, targeting the
junction of SCARB1 exon 2-3 which is conserved across
all isoforms; HS00969819_m1 for SR-BI (includes exon
12), targeting the junction of exons 11-12; and a custom
assay designed for SR-BII (excludes exon 12), with for-
ward primer 5’TCCCTGTCATCTGCCAAATCC-3’,
reverse primer 5’-GGCTGGCTCACGGTGT-3’ and
probe 5’-CCTCAGGACCTTGGCTCC-3’ targeting the
junction of exons 11-13. All three mRNA assays were
normalized to a PPIA mRNA control (ABI MGB probe
and primer set assay ID Hs99999904_m1).
The data were analyzed using the ΔΔCt method, with
a threshold set in the linear range of amplification.
The cycle number at which any particular sample
crossed that threshold (Ct) was then used to
determine fold difference. Fold difference was calculated
Table 1 SCARB1 SNPs evaluated in the Rancho Bernardo
Study.
Location rs number Minor
allele
Allele
frequency
Hardy-
Weinberg
p value
Tag SNPs
3’ rs838881 G 0.31 0.07
3’ rs838883 T 0.07 0.26
IVS12 rs701106 A 0.16 0.41
IVS12 rs7977729 C 0.29 0.60
IVS11 rs838893 T 0.31 0.41
IVS9 rs9919713 T 0.04 0. 40
IVS9 rs1031605 T 0.20 0.12
IVS7 rs989892* G 0.47 0.46
IVS7 rs838905 C 0.04 0.31
IVS6 rs838900 G 0.08 0.90
IVS2 rs4765615 T 0.47 0.40
IVS2 rs745529 T 0.37 0.006
IVS1 rs11057830 A 0.15 0.45
IVS1 rs10846745 G 0.44 0.85
IVS1 rs7135223 A 0.40 0.12
IVS1 rs12581963 A 0.08 0.69
IVS1 rs12580803 G 0.17 0.59
IVS1 rs10773107 A 0.48 0.50
IVS1 rs10744182 C 0.42 0.84
IVS1 rs4765180 T 0.43 0.97
IVS1 rs7954519 G 0.20 0.44
IVS1 rs4765621 T 0.33 0.12
IVS1 rs12229555 C 0.21 0.86
IVS1 rs10773109 G 0.45 0.90
IVS1 rs12582221 A 0.44 0.48
IVS1 rs12370382 T 0.39 0.84
IVS1 rs3924313 A 0.33 0.51
IVS1 rs11057851 A 0.11 0.53
IVS1 rs11057852 T 0.05 0.76
IVS1 rs10773111 T 0.42 0.38
IVS1 rs4765181 A 0.39 0.99
IVS1 rs11615630 T 0.40 1.00
5’ rs4379922 C 0.37 1.00
5’ rs10846760 T 0.36 1.00
Additional
SNPs
IVS11 rs838892 A 0.31 0.47
IVS11 rs838895 G 0.32 0.82
IVS11 rs838896 C 0.34 0.52
*Proxy SNP for exon 8 SNP evaluated in previous studies (rs5888)
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-ΔΔCt; ΔCt = [Ct(target)-Ct (PPIA)]. ΔΔCt = [ΔCt
(sample)]-[ΔCt(calibrator)], where target is SCARB1, SR-
BI or SR-BII. The calibrator was a single, randomly
selected control liver sample used in each plate for nor-
malization within and across runs and used in creation
of standard curves. Each sample was run in duplicate in
two independent plates, over all 4 repeats. The ΔΔCt
results obtained with the four repeats were average to
determine the fold expression level used in the associa-
tion analysis.
We controlled for DNA contamination by running
three randomly selected, RNA control samples that were
not converted to cDNA and no-cDNA/RNA sample in
each plate. No observable amplification was detected. In
addition for assay validation we generated standard
curves for each target and reference assay, using differ-
ent amounts of human liver total RNA (1-1000 ng). In
addition, the slope of the relative efficiency plot for each
target and internal control were determined to validate
the assays, i.e. SCARB1, SR-BI or SR-BII and PPIA.T h e
slope in the relative efficiency plot for each target and
PPIA were determined, and showed a standard value
(<0.1) required for the validation of the relative quanti-
tative method. (Additional file 1, Figure S1).
SCARB1 genotyping
Genomic DNA was isolated using conventional protocol
by Qiagen kits (Qiagen, Inc., Valencia, CA). SCARB1 geno-
types were assayed in genomic DNA isolated from frozen
whole blood samples from subjects in the Rancho Ber-
nardo Study and from the liver tissues and HepG2 cell
line using either the Sequenom iPLEX™ multiplex mass
spectrometry genotyping system (Sequenom, Inc, La Jolla,
CA) or using the 5’ nuclease assay with allele specific Taq-
Man probes[34]. The percent missing genotypes and
Hardy-Weinberg Equilibrium were evaluated using Haplo-
view software[32] as a means of quality control.
Statistical analysis
SAS statistical software, Version 9.1 (SAS Institutes,
Cary, NC) was used for all statistical analyses. The
ggplot2 package[35] of the R language was also used for
plots[36]. The association between each SCARB1 SNP
and levels of total cholesterol, LDL cholesterol, triglycer-
ides, HDL cholesterol and the triglyceride:HDL choles-
terol ratio in the Rancho Bernardo Study was assessed
with Analysis of Variance (ANOVA). Triglycerides, HDL
cholesterol, LDL cholesterol, and the TG/HDL choles-
terol ratio were natural log (ln) transformed to improve
normality of the residuals. SNP genotypes were coded in
an additive model, except for SNPs where the minor
allele frequency was below 5%, in which case heterozy-
gous and homozygous variant genotypes were pooled to
test a dominant model. All models controlled for age
(continuous) and current estrogen therapy status. Inter-
actions between SNPs and estradiol levels (based on ter-
tile cutoffs) were determined by introduction of a cross-
product term in the model.
Differences in overall SCARB1, SR-BI and SR-BII
expression in liver samples were examined by sex and
by presence/absence of SCARB1 allelic variants using
standard linear regression analysis, controlling for post-
mortum interval and age. Genotypes were coded in a
dominant model (homozygous variant and heterozygote
genotypes pooled) because of small numbers. Genotype
by sex interaction was determined by inclusion of a
cross product term in the model. Expression levels were
natural log (ln) transformed for analysis. The proportion
of SR-BI and SR-BII out of total SCARB1 was deter-
mined by calculating the ΔΔct ratios (i.e. SR-BI or SR-
BII/overall SCARB1).
This study was approved by the Institutional Review
Boards at Duke University.
Results
Genotype associations with lipid traits in women from
the Rancho Bernardo Study
Minor allele frequencies for the SCARB1 SNPs typed in
this study ranged from 0.04 to 0.44. The average call
rate was 97% and one SNP had nominally significant
Table 2 Demographic characteristics and SCARB1 SNP minor allele carrier frequencies in 93 post-mortem liver
samples, obtained from otherwise healthy Caucasian adults.
Characteristic Males (all) (n = 41) Females (all) (n = 52) Females < 45 years old (n = 43)
Age (years) 40.9 ± 12.1 32.2 ± 13.8 27.8 ± 9.4
PMI (hours) 14.1 ± 5.9 17.2 ± 7.3 17.0 ± 7.5
rs7977729 (C) 0.41 0.50 0.49
rs838891 (G) 0.56 0.54 0.53
rs838892 (A) 0.56 0.53 0.52
rs838893 (T) 0.56 0.52 0.51
rs838895 (G) 0.54 0.54 0.53
rs838896 (C) 0.51 0.58 0.58
rs10846744 (G) 0.39 0.25 0.28
PMI = post mortem interval. Age and PMI are presented as means ± standard deviation.
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(Table 1). Characteristics of women from the Rancho
Bernardo Study are shown in Table 3. We modeled the
interaction between the SCARB1 SNPs and estradiol
levels on serum total cholesterol, triglycerides, HDL
cholesterol, LDL cholesterol and the triglyceride:HDL
cholesterol ratio among women not currently taking
estrogen therapy. Two SNPs on the same haplotype
block showed significant evidence of genotype by estra-
diol interaction (p < 0.05). The tag SNP rs838893
showed the strongest evidence of interaction for HDL
cholesterol (p = 0.006), triglycerides (p = 0.001) and the
triglyceride:HDL cholesterol ratio (p = 0.0005). This
common variant (minor allele frequency 0.31) lies on a
haplotype block spanning intron 11 to intron 12 of
SCARB1. We examined additional SNPs on this block,
all of which showed a similar pattern of significant asso-
ciations (Figure 1). Figure 2 illustrates how at low levels
of estradiol, the variant allele, G’, of the most significant
of these SNPs, rs838895, was associated with lower
levels of triglycerides and high levels of HDL cholesterol,
but at increasing levels of estradiol, the opposite was
found. Importantly, this SNP showed no association
with estradiol levels (p = 0.40). Results for another sig-
nificant SNP, rs838896, are also shown in Figure 2 for
comparison with results from the livers, presented
below. Similar trends were seen for all assayed SNPs on
that haplotype block. No significant interaction was
found between any of the SCARB1 tagging SNPs and
current use of estrogen therapy for HDL-C (p = 0.34) or
triglycerides (p = 0.53).
Expression levels and presence of alternative splice
variants in liver tissue
Given the existence of alternative splice forms of
SCARB1 involving inclusion/exclusion of exon 12, we
hypothesized that a SNP located within the associated
haplotype block may modulate splicing efficiency. We
quantified the amounts of the full-length SR-BI isoform
(including exon 12), the alternative SR-BII isoform
(exon 12 skipping) and overall SCARB1 mRNA (all
splice forms) in human liver tissues from 93 healthy
individuals. SR-BI showed higher expression levels than
SR-BII, consistent with other studies, but accounted for
less than half of the overall SCARB1 expression: on
average SR-BI accounted for 39 ± 19% and SR-BII 3.5 ±
1.8% of overall SCARB1 expression.
The effect of sex and genotype on alternative splicing of
SCARB1 in human liver tissues
In order to determine the functional consequences of
SCARB1 SNPs, we carried out genetic association analy-
sis of the associated SNPs and expression of SCARB1.
We genotyped seven SNPs, including six within the
associated haplotype block, which spans intron 11 to
intron 12 of SCARB1, and one outside the region in 93
commercially available liver samples. All SNPs were in
Hardy-Weinberg Equilibrium and showed linkage dise-
quilibrium patterns consistent with those seen in the
Rancho Bernardo Study (not shown). One outlier sam-
ple was removed after performing linear regression diag-
nostics and the reference liver sample was also not
included, leaving a sample size of 91 (57% female).
Because of the apparent estrogen dependency of
SCARB1 variants on lipid levels, we examined primary
sex effects, primary genotype effects and interactive
effects between sex and SCARB1 genotype on mRNA
expression.
Previous studies found that estrogen treatment of
human HepG2 cells results in a decrease in SR-BI and
increase of SR-BII[24,27]. First, as a proxy for estrogen
effects, we examined male-female differences in liver
expression of SR-BI, SR-BII and overall SCARB1.W e
found significantly lower levels of overall SCARB1,
SR-BI isoform and SR-BII isoform in female versus male
livers (Figure 3). Next, we examined the effect of each
of the seven SNPs on expresssion in the combined liver
samples from men and women, but no significant asso-
ciations were found. We then repeated this analysis,
assessing SNP by sex interaction for all SNPs. We found
modest evidence of interaction between sex and
SCARB1 SNP rs838896 influencing expression of the
SR-BI isoform (p = 0.09), which became stronger when
restricting analysis to subjects ≤45 years old (p = 0.04),
leading us to carry out sex-stratified analyses. As shown
in Figure 4, presence (+) of the rs838896 minor allele,
C, was associated with significantly lower levels of SR-BI
in liver tissue from women (p = 0.01) but not in men
(p = 0.65). Restricting the analysis to liver tissue from
women <45 years of age, the genotype association
became stronger: in younger women, presence of at
least one copy of the rs838896C allele conferred a 38%
lower level of SR-BI (p = 0.002), a non-signfiicant 26%
lower level of SR-BII (p = 0.16) and a 28% lower level of
overall SCARB1(p = 0.02), compared to young women
not carrying this allele. Similar, but less significant asso-
ciations were seen for other SNPs on the haplotype
block (rs7977729, rs838891, rs838892, rs838893,
rs838895, and rs838896). It is noteworthy that rs838895,
which showed the strongest association with lipids in
the Rancho Bernardo Study, did not reach significance
in the liver gene expression analysis (e.g. in females <45,
the p values were 0.07, 0.13 and 0.54 for association
with overall SCARB1, SR-BI and SR-BII expression).
This may be due to differences in linkage disequilibrium
between rs838895 and rs838896 in the two studies: r
2 =
0.80 in Rancho Bernardo and r
2 = 0.62 in the livers. No
associations were found for the one SNP outside of the
block (rs10846744). We then compared relative levels of
each splice form (ratio to overall SCARB1 expression) in
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Page 5 of 12Figure 1 SCARB1 SNPs associated with lipid levels in an estradiol-dependent manner in postmenopausal women. Top panel - Intron/
exon structure of SCARB1 isoforms, SR-BI and SR-BII; Middle two panels - P value for interaction between SCARB1 SNPs and endogenous estradiol
levels for serum lipid levels in the Rancho Bernardo Study; Bottom panel - haplotype block representing associated interval (numbers are r
2
values measuring pairwise linkage disequilibrium between SNPs). SNPs are ordered based on their position in the gene and from left (3’) to right
(5’) ends of the gene. TC = total cholesterol; LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol; Trig =
triglycerides; TGHDL = triglyceride:HDL-C ratio.
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genotype: Carriers of the rs838896 minor allele
(rs838896+) had on average 41 ± 4% SR-BI and 3.9 ±
0.4 % SR-BII while non-carriers (rs838896-) had average
levels of 47 ± 5% and 3.6 ± 0.4%, respectively.
Discussion
The results of our study in a community-based cohort
of post-menopausal women demonstrate that poly-
morphisms of SCARB1 are associated with HDL choles-
terol and triglyceride levels in an endogenous estrogen-
dependent fashion. Specifically, variant alleles of
SCARB1 in a block encompassing intron 11 to intron 12
were associated with increased triglycerides and
decreased HDL cholesterol in the presence of high levels
of endogenous estradiol, but the opposite was seen at
lower levels of estradiol. Importantly, these effects were
observed among post-menopausal women who already
have low levels of estradiol, suggesting that small
changes in endogenous estradiol can impact the associa-
tion of SCARB1 genotype on serum lipid levels.
Figure 2 Effect of SCARB1 genotype on serum lipid levels by tertile of endogenous estradiol. Shown are mean values of HDL cholesterol
and triglycerides with 95% confidence intervals for subjects with 0, 1 or 2 copies of the rs838895 (panels A and B) and rs838896 (panels C and
D) minor alleles. Endogenous estradiol tertiles were: low (7-17 pmol/L); medium (18-24 pmol/L); high (25-58 pmol/L).
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between these same genotypes and current use of oral
estrogen therapy, as one might expect, nor did we find
evidence of genotype by endogenous estradiol interac-
tion for two SNPs reported to interact with oral estro-
gen therapy in our previous study of HDL cholesterol
(data not shown). These discrepancies may be related to
the marked perturbation of hepatic metabolism pro-
duced by oral estrogen therapy, including increased
plasma levels of VLDL, and HDL, and reduced plasma
LDL[37,38]. Oral estrogen is administered in high doses
due to poor systemic bioavailability averaging 5%[39]
and thus hepatocyte exposure to oral estrogen may be
magnified, exceeding the physiological range. Another
difference between oral and endogenous estrogen is that
the former has typically involved equine estrogens (par-
ticularly during the period of sample collection for this
study) whereas estradiol is the most active endogenous
estrogen. Their effects on gene expression relevant to
lipid metabolism may be quite different. Another
possibility is that the SNPs that interacted with estrogen
therapy in our previous study could reflect other differ-
ences between users and non-users of estrogen therapy,
the former being younger and having lower fasting glu-
cose[28], as well as having lower testosterone (unpub-
lished data).
We further demonstrate in the current study that in
liver tissues from young, adult females (but not males)
the SCARB1 rs838896 minor allele from the identified
haplotype block is associated with lower overall expres-
sion, driven in large part by the SR-BI isoform. Hence,
increased expression of SR-BI may underlie the protec-
tive lipid profiles observed in women with both high
levels of estradiol and homozygous for the rs838896
wildtype allele as observed in the Rancho Bernardo
Study, and could account for underlying sex differences
in SCARB1 genetic associations with lipids described in
previous studies[11-15,17,18].
Previous studies in rodent models and human HepG2
cell lines indicate that estrogen down-regulates SR-BI
and up-regulates SR-BII isoforms[24,27]. Thus, one
would expect that women (specifically pre-menopausal
women with higher levels of estrogen) would have lower
levels of SR-BI and higher levels of SR-BII than men.
Our findings in a series of human liver tissues confirm
that females have significantly lower levels of hepatic
SR-BI expression compared to males, but SR-BII levels
were not higher; in fact levels of SR-BII were lower in
females, especially among carriers of the SCARB1
rs838896 minor allele (the same genotype of HepG2 cell
lines, data not shown). Although experimental results in
human liver tissue may not equate with those in rodent
liver or cultured human HepG2 cell lines, these discre-
pant findings warrant further investigation. In the study
by Graf[27], antibodies specific to the 3’ end of the
SCARB1 protein were used to distinguish SR-BI from
SR-BII in human HepG2 cell lines treated with 17 estra-
diol. In the study by Zhang[24], treatment of HepG2
cell lines under the same conditions as Graf et al.d i d
Table 3 Baseline characteristics of postmenopausal Caucasian women from the Rancho Bernardo Study in the overall
cohort and by low, moderate or high estradiol (E2) tertile in the subset with estradiol measures available.
Characteristic (mean ± SD) All women Low E2 Mod E2 High E2
Sample size (784) (180) (140) (173)
Age (years) 69.1 ± 8.6 71.1 ± 8.2 70.8 ± 8.4 68.5 ± 9.2
Waist circumference (cm) 78.0 ± 9.1 75.8 ± 8.0 78.2 ± 8.6 80.9 ± 9.6
BMI (kg/m
2) 24.1 ± 3.6 23.0 ± 3.0 23.9 ± 2.9 25.5 ± 4.0
Total cholesterol (mmol/L) 5.9 ± 1.0 5.9 ± 1.1 6.1 ± 1.0 6.0 ± 0.94
HDL cholesterol (mmol/L) 1.8 ± 0.5 1.8 ± 0.45 1.8 ± 0.47 1.6 ± 0.43
LDL cholesterol (mmol/L) 3.5 ± 1.0 3.6 ± 1.0 3.7 ± 1.0 3.8 ± 0.9
Triglycerides (mmol/L)* 1.1 ± 0.8 1.0 ± 0.7 1.1 ± 0.8 1.2 ± 1.0
Estradiol levels (pmol/L)* - 11.0 ± 7.3 18.4 ± 3.7 29.4 ± 11
* Median and interquartile range
Figure 3 Sex differences in mRNA expression in human liver
tissue. Shown are average ΔΔCt values with standard error bars for
full length SR-BI isoform, SR-BII and overall SCARB1, all relative to
PPIA control in 91 human liver tissue, controlling for effects of age
and post-mortem interval.
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Page 8 of 12Figure 4 mRNA expression in human liver tissue by SCARB1 genotype and sex. Results shown are average ΔΔCt values with standard error
bars for A.) Full length SR-BI isoform; B.) SR-BII and C.) overall SCARB1, all relative to PPIA control. Rs838896+ refers to carrier of the G allele (GG
and GC); Rs838896- refers to genotype CC.
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Page 9 of 12not produce any changes in SR-BI or SR-BII. Only after
subsequent introduction of estrogen receptor and treat-
ment with synthetic equine estrogen did they recapitu-
l a t et h ei n c r e a s ei nS R - B I Ie x p r e s s i o nn o t e db yG r a fet
al. However, SR-BII was not measured directly, but was
determined by calculating the difference between overall
SCARBI and SR-BI levels. SR-BII, resulting from skip-
ping of exon 12, is the most studied alternatively splice
form, but may not be the only splice form. Additional
splice forms have been described in genomic databases
such as Entrez Gene Aceview[40], including one form
that differs dramatically in the 3’ end of the gene, miss-
ing both exons 12 and 13 and retaining a large segment
of intron 11 as coding. We confirmed the expression of
this splice form in human brain and liver tissues (data
not shown). Thus, differences in our findings from
others may relate to the method of detection of SR-BII
expression and the possible existence of additional iso-
forms of SCARB1 not accounted for in any published
analyses to date.
Recently, Zhang and colleagues proposed that estrogen
regulation of alternative splicing of SCARB1 in the rat
occurs via regulatory splicing factors that interact with
regulatory sequences in intron 11 of SCARB1[24,41].
The human SCARB1 polymorphisms most strongly
associated with estrogen-dependent splicing and lipid
traits in our study are located on a haplotype block
spanning intron 11 to intron 12. The coincidental loca-
tion of the putative regulatory region identify by Zhang
and the presence of SNPs controlling SR-BI isoform
expression in our study lead us to suspect that the poly-
morphism underlying our observed association impacts
the estrogen-dependent regulation of SCARB1 expres-
sion, perhaps of specific isoforms. Our data do not sup-
port an effect of SCARB1 SNPs on relative amounts of
SR-BI or SR-BII in liver, but the possibility that other
isoforms are impacted by these gene variants should be
explored. Whether the rs838896 variant is the causal
variant or in linkage disequilibrium with the causal var-
iant remains to be determined in follow up functional
studies using cell culture and other systems.
Both HDL cholesterol and triglyceride levels are sexu-
ally dimorphic traits: levels of HDL cholesterol are
20-25% higher in women than men and these differ-
ences persist over time; triglyceride levels, on the other
hand, start out slightly lower in women compared to
men in young adulthood, but around the time of meno-
pause, triglyceride levels rise dramatically in women[42].
We propose that this rise in triglycerides may be attri-
b u t a b l ei np a r tt oe s t r o g e nr e g u l a t i o no fSCARB1,a n d
that the protection afforded by estrogen in younger
women may be limited to women with a certain
SCARB1 genotype. It is interesting to note that SCARB1
is also a co-receptor for the Hepatitis C virus (HCV)
and that increased expression of both SR-BI and SR-BII
isoforms increase infectivity in vitro[43]. Additionally,
women generally have better outcomes of HCV infec-
tion, perhaps related to estrogen [44], leading us to
speculate on the role of estrogen-mediated expression of
SCARB1 in outcomes of Hepatitis C infection.
Our study of the phenotypic consequences of SCARB1
variation was carried out in a community-based sample of
post-menopausal Caucasian women who were not selected
based on any disease phenotype. The samples and data
were collected before the widespread use of lipid lowering
therapy, thus reducing confounding by treatment. Yet,
there are some caveats of our study, including that estra-
diol assays were measured only once. Although single
measurements of most hormones reliably characterize
average levels over a two to three year period, estradiol
levels are less reproducible[45,46]. However, estradiol was
measured in morning fasting samples, and among postme-
nopausal women estradiol does not show significant diur-
nal variation[47]. Moreover, it should be noted that this
was an elderly population of women, with relatively low
levels of estradiol; we might expect estrogen effects to be
more pronounced in a younger population. As with most
large scale SNP association studies, ours is also prone to
false positive associations, the result of multiple testing.
Replication of the observed associations in other study
populations is warranted.
Conclusions
In summary, our work has detected sex-specific expres-
sion of SCARB1 isoforms in vivo in human liver tissue
and identified polymorphisms in intron 11 of the gene
that modify this effect. We further found these same
genetic variants to influence triglyceride and HDL cho-
lesterol levels in an endogenous estrogen-dependent
manner in a human population study. Thus, estrogen
regulation of SCARB1 may contribute to the observed
sexual dimorphism of lipid levels and highlights the
importance of considering sex-dependent effects of gene
variants on serum lipid levels.
Additional file 1: Figure S1. Validation curves of the ΔΔ real-time
gene expression assays. Shown are curves for overall SCARB1, SR-BI and
SR-BII versus endogenous control (PPIA). Relative efficiency plots were
formed by plotting the log input amount (ng of total RNA) versus the
ΔCt (Ct SCARB1 -C tPPIA), for example. The slopes are <0.1 which
indicates the validation of the ΔΔCt calculation relative to the reference
controls in the range between 1-100 ng RNA.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2350-11-9-
S1.TIFF]
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